Elizabeth Takacs, MD
Urology · Mason City, IANPI 1447229901
Payments from drug & device makers
What this record shows
Medtronic accounts for 60.5% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $1,735, more than ten times the $59 reported in 2019.
Across 55 payments — averaging $75.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Valencia Technologies Corporation$683
- Urovant Sciences Inc$172
- Sumitomo Pharma America, Inc.$135
- Astellas Pharma US Inc$106
- Boston Scientific$91
- plus $450 from 13 others
Across 8 payments — averaging $8221.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$66K
What the payments were for
- Travel & lodging$2,38758%
- Food & beverage$1,75342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 23 | $2,503 |
| Valencia Technologies Corporation | 4 | $683 |
| Urovant Sciences Inc | 1 | $172 |
| Sumitomo Pharma America, Inc. | 2 | $135 |
| Astellas Pharma US Inc | 1 | $106 |
| Boston Scientific | 2 | $91 |
| Coloplast | 4 | $72 |
| Dendreon Pharmaceuticals LLC | 3 | $68 |
| AbbVie | 1 | $50 |
| Pfizer | 3 | $50 |
| Axonics, Inc. | 2 | $37 |
| Urogen Pharma, Inc. | 2 | $36 |
| Calyxo, Inc. | 1 | $25 |
| Teleflex LLC | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Endo USA, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTAVIVA$858
- eCoin Device Kit$548
- INTERSTIM$437
- GEMTESA$293
- XTANDI$106
How this compares
$4,140 in reported general payments places this provider in the 65th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 107 | $53,993 |
| MyrbetriqMirabegron | 65 | $36,447 |
| Estradiol | 135 | $10,024 |
| Methenamine Hippurate | 88 | $5,537 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 30 | $3,168 |
| Solifenacin Succinate | 113 | $3,157 |
| Oxybutynin Chloride ErOxybutynin Chloride | 117 | $1,873 |
| Trospium Chloride ErTrospium Chloride | 19 | $1,747 |
| Gentamicin Sulfate | 28 | $1,659 |
| Cephalexin | 142 | $728 |
| NitrofurantoinNitrofurantoin Macrocrystal | 29 | $569 |
| Terazosin Hcl | 90 | $517 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $387 |
| Tamsulosin Hcl | 38 | $342 |
| Hydroxyzine Hcl | 13 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $135 | $53,993107 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $36,44765 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 114 urology providers in Iowa.
Other urology in Mason City
- Steven ThomaMason City$5K
- Timothy MulhollandMason City$3K
- Kevin RierMason City$2K
- Christopher AdamsMason City$1K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Kevin BirusinghDes Moines$59K
- Ryan DornbierClive$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.